Enlivex Therapeutics Ltd. announced the appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.36 USD | +0.75% | -2.86% | -49.63% |
May. 28 | Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall | MT |
Apr. 22 | Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.63% | 27.79M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- ENLV Stock
- News Enlivex Therapeutics Ltd.
- Enlivex Therapeutics Ltd. Appoints Andrew Singer to Its Board of Directors